Mizuho on BridgeBio Pharma (BBIO): 'We believe that any such potential transient weakness could represent a potential entry point opportunity'

June 8, 2026 10:05 AM

Mizuho analyst Salim Syed reiterated an Outperform rating and $106.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst comments "The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found